Answers are grounded in this paper and cite their sources.
In this issue of Blood Cancer Discovery, Pomeroy and Palmer present a new mathematical model, incorporating both inter- and intra-patient heterogeneity, to accurately predict outcomes for first-line combination therapies in diffuse large B-cell lymphoma. Their quantitative framework opens a range of possibilities for optimizing trial design and lymphoma therapy with potential to expedite clinical development. See related article by Pomeroy and Palmer, p. 254.
No takes yet. Share an insight, caveat, or question.
Goldstein et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: